Ex parte IIMORI et al. - Page 7


             Appeal No. 1998-1866                                                                                    
             Application 08/406,883                                                                                  
                           In response to the PTO’s asserted prima facie case the applicant may                      
                    argue that the inference of lack of novelty was not properly drawn, for example if               
                    the PTO did not correctly apply or understand the subject matter of the reference,               
                    or if the PTO drew unwarranted conclusions therefrom.  However, when the PTO                     
                    shows sound basis for believing that the products of the prior art and the                       
                    applicant are the same, the applicant has the burden of showing that they are                    
                    not.  In re King, 801 F.2d 1324, 1327, 231 USPQ 136, 138 (Fed. Cir. 1986); In re                 
                    Ludtke, 441 F.2d 660, 664, 169 USPQ 563, 566 (CCPA 1971).                                        
             See also In re Fitzgerald, 619 F.2d 67, 70, 205 USPQ 594, 597 (CCPA 1980) (“Thus, the                   
             dispositive issue is whether appellants have proved that the Barnes process does not                    
             result in fasteners having the claimed crystallization shrinkage.”).3                                   
                    Here, we believe the facts that the respective fungi are white-rot fungi and                     
             degrade lignin provide the thinnest of margins, if at all, to conclude that the respective              
             microbes are “identical or substantially identical.”  As explained above, if these are the              
             only two relevant properties needed in order to invoke the pri nciples of In re Best, we                
             dare say appellants should be concerned that a multitude of rejections are possible                     
             which have yet to be made.                                                                              
                    Be that as it may, appellants did not argue in this appeal that the examiner                     
             unreasonably shifted the burden of providing such evidence.  Rather, as explained                       
             above, appellants’ position is premised upon the fact that Blanchette strain F361                       
             possesses laccase activity while their strain SKB-1152 does not.  The examiner has not                  
             accepted this argument stating at pages 5 -6 of the Examiner’s Answer:                                  

                                                                                                                     
             3 To avoid confusion as to the facts and reasons supporting an examiner’s rejection under these         
             circumstances and consistent with the “102/103” language used by the the court in cases such as Spada   
             and Best, it may be better for an examiner to simply state that the claim is considered to be unpatentable
             under 35 U.S.C. § 102/103 on the basis of a specified reference.  That opening statement should be      
             followed by the examiner’s facts and reasoning as to why it is proper to shift the burden of going forward
             to applicant.  It would be helpful if in stating the rejection the examiner relied upon cases such as Best,
             Spada and Fitzgerald so there is no confusion as to the approach taken by the examiner in rejecting the 
             claim. Again, under these circumstances the examiner is not in a position to make the specific findings 
             needed to conclude that the claim is either anticipated or obvious on the basis of the reference.       

                                                         7                                                           



Page:  Previous  1  2  3  4  5  6  7  8  9  10  Next 

Last modified: November 3, 2007